Various healthcare and government insurance providers are offering reimbursement for diagnosis of chronic disorders such as cervical cancer screening. For instance, Medicare – U.S. government-funded health insurance provider, provides reimbursement to people who are of age 65 or older and some younger population with disabilities. Moreover, for cervical cancer diagnosis, such plans cover reimbursement for one pap test every three years or a combination of pap test & HPV testing every five years. Favorable government initiatives as such are expected to drive the demand for Human Papillomavirus (HPV) testing market in the years to come.

HPV testing is gradually becoming crucial for cervical cancer screening, according to recent report published by Persistence Market Research. The report estimates that in 2017, the global market for Human Papillomavirus testing will reach an estimated value of US$ 629.4 Mn. Improving reimbursement scenario, coupled with high sensitivity of Human Papillomavirus testing in low resource setting, is expected to drive the market’s growth. By the end of 2025, the global market for Human Papillomavirus testing will have soared at 7.6% CAGR, bringing in more than US$ 1,100 Mn in revenues.

Request A Sample Report@ https://www.persistencemarketresearch.com/samples/11737

A key limitation for Human Papillomavirus testing is that these tests are confined to women as men undergoing HPV testing have higher risks of getting infected with genital warts. In addition to this, patients are not willing to take Human Papillomavirus tests because of lack of diagnosis options. Over-diagnosis of Human Papillomavirus testing can cause more complications and can even risk the life of patients. Meanwhile, the global revenues from Human Papillomavirus testing are being lowered due to availability of HPV vaccines. Preference to HPV vaccines is directly impeding the revenues arising from Human Papillomavirus testing. High cost of HPV screening test, overburdened healthcare system, low awareness on HPV prevention, and imperfections in organized screening programs are some other challenges impacting the growth of global HPV testing market.

Summary of Table of Content

1. Executive Summary

2. Market Introduction

3. Human Papillomavirus (HPV) Testing Market Opportunity Analysis

4. North America Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025

5. Latin America Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025

6. Europe Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025

7. Asia Pacific Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025

8. Middle East & Africa Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025

9. Forecast Factors: Relevance and Impact

10. Forecast Assumptions

11. Competition Landscape

12. Global Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025, By Region

13. Global Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025, By Product

14. Global Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025, By End User

15. Global Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025, By Applications

16. Global Human Papillomavirus (HPV) Testing Market Analysis 2012–2016 and Forecast 2017–2025

Request to Browse Full Table of Content, figure and Tables @ https://www.persistencemarketresearch.com/market-research/human-papillomavirus-testing-market/toc